Citius Oncology (CTOR) Competitors $5.32 +0.10 (+1.92%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$5.29 -0.03 (-0.56%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. PHAT, CRON, REPL, PHAR, XERS, TRVI, VIR, NUVB, IMTX, and ANABShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Phathom Pharmaceuticals (PHAT), Cronos Group (CRON), Replimune Group (REPL), Pharming Group (PHAR), Xeris Biopharma (XERS), Trevi Therapeutics (TRVI), Vir Biotechnology (VIR), Nuvation Bio (NUVB), Immatics (IMTX), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Phathom Pharmaceuticals Cronos Group Replimune Group Pharming Group Xeris Biopharma Trevi Therapeutics Vir Biotechnology Nuvation Bio Immatics AnaptysBio Citius Oncology (NASDAQ:CTOR) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Which has stronger valuation and earnings, CTOR or PHAT? Citius Oncology has higher earnings, but lower revenue than Phathom Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/APhathom Pharmaceuticals$55.25M11.07-$334.33M-$5.24-1.67 Do analysts recommend CTOR or PHAT? Citius Oncology presently has a consensus price target of $3.00, suggesting a potential downside of 43.61%. Phathom Pharmaceuticals has a consensus price target of $17.50, suggesting a potential upside of 99.66%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor CTOR or PHAT? In the previous week, Citius Oncology had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 2 mentions for Citius Oncology and 1 mentions for Phathom Pharmaceuticals. Citius Oncology's average media sentiment score of 0.00 equaled Phathom Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, CTOR or PHAT? Citius Oncology has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Is CTOR or PHAT more profitable? Citius Oncology has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -422.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -53.88% -18.86% Phathom Pharmaceuticals -422.42%N/A -90.11% Do institutionals and insiders hold more shares of CTOR or PHAT? 70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 4.6% of Citius Oncology shares are held by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryPhathom Pharmaceuticals beats Citius Oncology on 8 of the 12 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$380.66M$2.88B$5.49B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E RatioN/A21.5627.4720.28Price / SalesN/A244.81408.86121.46Price / CashN/A41.9536.6357.47Price / Book8.317.518.095.68Net IncomeN/A-$55.05M$3.17B$248.96M7 Day Performance18.22%4.61%2.81%3.30%1 Month Performance466.98%4.89%3.67%5.20%1 Year PerformanceN/A5.84%35.41%21.37% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology0.1753 of 5 stars$5.32+1.9%$3.00-43.6%N/A$380.66MN/A0.00N/AGap DownPHATPhathom Pharmaceuticals3.6083 of 5 stars$9.47-9.1%$17.50+84.8%-14.5%$727.46M$55.25M-1.81110High Trading VolumeCRONCronos Group2.3339 of 5 stars$1.87+0.5%N/A-12.1%$717.37M$117.61M14.39450News CoverageREPLReplimune Group4.0949 of 5 stars$9.23-0.4%$20.83+125.7%+16.8%$714.59MN/A-3.01210News CoverageAnalyst ForecastPHARPharming Group2.9362 of 5 stars$10.49+0.3%$30.00+186.1%+23.1%$710.92M$297.20M-52.42280Positive NewsGap UpXERSXeris Biopharma3.9172 of 5 stars$4.64+2.9%$6.25+34.7%+128.6%$705.29M$203.07M-15.47290Positive NewsTRVITrevi Therapeutics3.3119 of 5 stars$5.75-3.5%$20.29+252.8%+120.8%$699.07MN/A-12.7820News CoverageAnalyst ForecastAnalyst RevisionVIRVir Biotechnology3.3826 of 5 stars$5.05-3.4%$32.86+550.6%-37.3%$698.10M$14.30M-1.20580News CoveragePositive NewsInsider TradeNUVBNuvation Bio3.453 of 5 stars$2.02+2.3%$7.17+255.7%-28.7%$690.73M$10.96M-0.8660High Trading VolumeIMTXImmatics2.9027 of 5 stars$5.42-3.4%$14.67+170.6%-52.3%$681.90M$144.15M-31.88260ANABAnaptysBio2.4708 of 5 stars$22.82-1.5%$42.38+85.7%-3.4%$680.75M$91.28M-4.71100News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Cronos Group Competitors Replimune Group Competitors Pharming Group Competitors Xeris Biopharma Competitors Trevi Therapeutics Competitors Vir Biotechnology Competitors Nuvation Bio Competitors Immatics Competitors AnaptysBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
